MarketCap
DBV Technologies S.A. DBVT
$ 11.55
4.62%
Facebook
X
Telegram
DBV Technologies S.A. ROCE Ratio | DBVT
Annual ROCE Ratio DBV Technologies S.A.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -83.7 | -337.72 | -52.48 | -44.53 | -85.51 | -72.35 | -78.55 | -129.64 | -102.19 | -44.89 | -13.92 | -20.55 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -13.92 | -337.72 | -88.84 |
Quarterly ROCE Ratio DBV Technologies S.A.
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -149.79 | -152.19 | -382.89 | -360.57 | -409.38 | -392.18 | -372.36 | -111.7 | -123.24 | -88.06 | -59.65 | -35.73 | -43.93 | -42.14 | -46.84 | -36.27 | -54.04 | -65.07 | -71.55 | -53.24 | -66.79 | -70.75 | -70.29 | -54.06 | -13.56 | -21.73 | -18.78 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -13.56 | -409.38 | -124.7 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Trevena
TRVN
|
460.86 | - | -46.58 % | $ 31.8 M |  USA |
 |
Immunovant
IMVT
|
-70.24 | $ 35.73 | 1.65 % | $ 6.52 B | USA |
 |
Virpax Pharmaceuticals
VRPX
|
1322.0 | - | -45.12 % | $ 2.85 M | USA |
 |
Oncorus
ONCR
|
-126.46 | - | -8.54 % | $ 3.19 M | USA |
 |
Y-mAbs Therapeutics
YMAB
|
-33.91 | - | - | $ 382 M | USA |
 |
Navidea Biopharmaceuticals
NAVB
|
166.56 | - | -2.99 % | $ 2.47 M | USA |
 |
InMed Pharmaceuticals
INM
|
-65.74 | $ 15.56 | 13.57 % | $ 64.8 M |  Canada |
 |
Stealth BioTherapeutics Corp
MITO
|
102.23 | - | - | $ 23.9 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Satsuma Pharmaceuticals
STSA
|
-151.52 | - | -0.9 % | $ 36.5 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-54.19 | $ 1.14 | -6.97 % | $ 97.2 M | USA |
 |
SpringWorks Therapeutics
SWTX
|
-57.81 | - | - | $ 3.48 B | USA |
 |
Metacrine
MTCR
|
-106.49 | - | - | $ 24.2 M | USA |
 |
Turning Point Therapeutics
TPTX
|
-24.94 | - | -0.13 % | $ 3.73 B | USA |
 |
Infinity Pharmaceuticals
INFI
|
235.39 | - | -46.98 % | $ 3.57 M | USA |
 |
OncoSec Medical Incorporated
ONCS
|
-604.93 | - | 31.87 % | $ 1.61 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Evelo Biosciences
EVLO
|
2172.8 | - | -14.46 % | $ 27.9 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
Morphic Holding
MORF
|
-25.64 | - | - | $ 2.42 B | USA |
 |
Novan
NOVN
|
-743.32 | - | -24.84 % | $ 2.64 M | USA |
 |
Genocea Biosciences
GNCA
|
-192.4 | - | -15.0 % | $ 3.04 M | USA |
 |
Eiger BioPharmaceuticals
EIGR
|
496.51 | - | -9.21 % | $ 2.55 M | USA |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
BELLUS Health
BLU
|
-19.87 | - | - | $ 2.47 B | Canada |
 |
bluebird bio
BLUE
|
857.68 | - | - | $ 546 M | USA |
 |
Intra-Cellular Therapies
ITCI
|
-10.16 | - | - | $ 13.6 B | USA |
 |
IGM Biosciences
IGMS
|
-432.99 | - | - | $ 76.9 M | USA |
 |
Marinus Pharmaceuticals
MRNS
|
-784.28 | - | - | $ 29.6 M | USA |
 |
Merrimack Pharmaceuticals
MACK
|
-10.87 | - | - | $ 216 M | USA |
 |
CASI Pharmaceuticals
CASI
|
-76.35 | - | - | $ 35.4 M | USA |
 |
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | USA |
 |
Sigilon Therapeutics
SGTX
|
-111.56 | - | - | $ 728 M | USA |
 |
Rubius Therapeutics
RUBY
|
-1179.34 | - | -33.55 % | $ 7.81 M | USA |
 |
Aptinyx
APTX
|
-163.42 | - | -39.0 % | $ 4.57 M | USA |
 |
TRACON Pharmaceuticals
TCON
|
1146.23 | - | -1.38 % | $ 46.8 M | USA |
 |
Mirati Therapeutics
MRTX
|
-76.22 | - | - | $ 3.3 B | USA |
 |
Revance Therapeutics
RVNC
|
208.95 | - | - | $ 309 M | USA |
 |
Allogene Therapeutics
ALLO
|
-71.55 | $ 0.93 | -11.99 % | $ 205 M | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
-67.64 | - | -37.48 % | $ 476 K | USA |
 |
Epizyme
EPZM
|
1150.39 | - | - | $ 249 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-1339.01 | - | -9.72 % | $ 5.89 M | USA |
 |
ORIC Pharmaceuticals
ORIC
|
-37.21 | $ 8.9 | -3.63 % | $ 781 M | USA |
 |
Forward Pharma A/S
FWP
|
-5.47 | - | -0.75 % | $ 18.7 M |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
-129.33 | - | 1.02 % | $ 90.8 M |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
-32.71 | - | - | $ 154 M | USA |
 |
Oyster Point Pharma
OYST
|
-97.1 | - | - | $ 300 M | USA |
 |
Nabriva Therapeutics plc
NBRV
|
-1333.89 | - | - | $ 4.55 M |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
-20.32 | - | - | $ 643 M | USA |
 |
NGM Biopharmaceuticals
NGM
|
-101.9 | - | - | $ 127 M | USA |